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Tuning the reaction pathways of phenanthroline-
Schiff bases: routes to novel phenanthroline
ligands†
Muhib Ahmed,a Denise Rooney, *a,b Malachy McCann,a Jamie Casey,a
Katie O’Sheaa and Brendan Twamleyc
Pyrido-phenanthrolin-7-one compounds are structural analogues of the cytotoxic alkaloid, ascididemin,
and would be expected to have interesting biological activities. Synthetic strategies are reported for a novel
simple route to form this class of ligand. 1,10-Phenanthrolin-5,6-dione reacts with L-phenylalanine alkyl
esters and their para-substituted analogues to form both a phenanthroline–oxazine and a pyrido-phenan-
throlin-7-one product. The nature of the major product is dependent on the electronic properties of the
para substituent. Successful metal coordination to the pyrido-phenanthrolin-7-one ligand is also presented.
Introduction
1,10-Phenanthroline, its organic derivatives and their associ-
ated metal complexes have been extensively studied for use as
optical devices,1,2 catalysts,3 chemosensors4 and in the for-
mation of metal organic frameworks.5 They have also found
use in biological applications as antimicrobial and anticancer
agents,6 and as DNA intercalators.7 There is significant interest
in developing routes to novel phenanthrolines by further deri-
vatisation of functionalised phenanthrolines.8 One such func-
tionalised phenanthroline, the quinone, 1,10-phenanthrolin-
5,6-dione (phendione), has been widely used as the starting
material for attaching moieties onto the phenanthroline
framework, via simple Schiff base condensation reactions with
primary amines.9,10 Previously, members of our group pub-
lished an unusual reaction of phendione with L-tyrosine
methyl ester hydrochloride to produce a phenanthroline–
oxazine compound (Scheme 1, Pathway (i) (R = OH, R′ =
Me)).11 It is proposed that the first step of this reaction is a
Schiff base condensation, followed by a cyclisation reaction to
form a new C–O bond, with a second molecule of phendione
acting as the dehydrogenating agent. 1,10-Phenanthrolin-5,6-
diol is always observed as side-product of the reaction. In
developing this reaction further, we observed that another
unusual competing cyclisation reaction could occur, depend-
ing on the amino acid ester substrate (Scheme 1, Pathway (ii)),
to form pyrido-phenanthrolin-7-one compounds.
The pyrido-phenanthrolin-7-one compounds are synthetic
analogues of the marine alkaloid, ascididemin (Fig. 1) which
is well-known to have substantial cytotoxic effects against a
number of tumour cell lines, including multidrug-resistant
cancer cells.12 Ascididemin can be isolated from natural
sources in minute amounts,13 while routes to its total syn-
thesis require multiple steps and are very challenging.14
Studies have revealed that some ascididemin synthetic ana-
logues can display greater anti-tumour activity than the natural
alkaloid,15 and there is much interest in developing routes to
Scheme 1 Competing reactions to form phenanthroline–oxazine
(pathway (i)) or pyrido-phenanthrolin-7-one (pathway (ii)) ring systems.
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ascididemin analogues.16 A recent development has been the
binding of ascididemin to ruthenium(II) in order to develop
metallo-anticancer complexes.17 In a related context there is
substantial interest in developing rhenium(I) tricarbonyl com-
plexes for their anticancer activity.18–21
Here we report the novel and simple one-pot route to
making ascididemin analogues from readily available starting
materials, the full structural characterisation of methyl 7-oxo-
4-phenyl-7H-pyrido[4,3,2-de][1,10]phenanthroline-5-carboxylate
(1a) and preliminary studies on forming a rhenium(I) tricarbo-
nyl complex with its propyl ester analogue (1b). We also give
some insights into the factors that control the direction of this
unusual reaction to form the pyrido-ligand product.
Results and discussion
Synthesis and characterisation of ligands
Reacting the amino acid ester, 4-nitro-L-phenylalanine ethyl
ester hydrochloride, with phendione gives the bright-red
pyrido product, ethyl 4-(4-nitrophenyl)-7-oxo-7H-pyrido[4,3,2-
de][1,10]phenanthroline-5-carboxylate (1c), in 30% yield as the
sole isolated product. Compound 1c was characterised using
HRMS, IR and NMR spectroscopy. Upon changing the amino
acid ester to L-phenylalanine methyl ester hydrochloride and
L-phenylalanine propyl ester hydrochloride both the phenan-
throline–oxazine and the pyrido-phenanthrolin-7-one products
were detected in the 1H NMR spectra of the reaction mixtures.
Bright-yellow crystals of the pyrido product, methyl 7-oxo-4-
phenyl-7H-pyrido[4,3,2-de][1,10]phenanthroline-5-carboxylate
(1a) were isolated (7% yield) from the L-phenylalanine methyl
ester reaction, whilst yellow crystals of the oxazine product,
propyl 2-phenyl-2H-[1,4]oxazino[2,3-f ][1,10]phenanthroline-3-
carboxylate (2) were isolated (3%) from the L-phenylalanine
propyl ester reaction. X-ray crystal structures of 1a (Fig. 2) and
2 (Fig. 3) were obtained. For 1a the tetracyclic ring system is
nearly planar and the C–C bond lengths are consistent with
the aromatic nature of this core. The phenyl ring lies at an
angle to the tetracycle (torsional angle C(17)–C(18)–C(19)–
C(20) of –60.7(5)°). There is a π ring interaction between adja-
cent tetracyclic rings with ring C8–N12 centroid-to-centroid
distance of 3.619(3) Å (with a shift of 1.533(6) Å). Compound 2
has a stereogenic centre at C9 but is a racemate. The phenyl
ring is almost orthogonal to the phenanthroline–oxazine
moiety (torsional angle C(8)–C(9)–C(19)–C(24)–77.2(3)°).
Packing of the molecule showed π–π interactions between the
phenanthroline rings (C12–C17, centroid-to-centroid 3.543(2)
Å, shift 0.383(5) Å) and H-bond interactions between adjacent
molecules for the H atoms on C9 and O(10) (3.383(4) Å), on
C13 and O(26) (3.398(4) Å) and on C24 and N1 (3.363(4) Å).
Investigation on product selectivity
To probe the issue of product selectivity, a study using LC-
mass spectrometry detection was carried out on the crude reac-
tion mixtures for a series of reactions. In the first instance, the
reaction of L-phenylalanine methyl ester with phendione was
carried out over a range of temperatures (Table 1). The results
clearly show that the two reactions are in competition, with
the pyrido-phenanthrolin-7-one product being favoured over
the oxazine at higher temperatures. From our initial obser-
vations, it appears that product formation is dependent on the
nature of the para substituent of the phenyl ring borne by the
amino acid ester. In this context, the LC-mass spectrometry
study was carried out with the reaction held at a fixed tempera-
ture (75 °C) on a number of amino acid methyl esters with
different substituents at the para position of the phenyl ring
(Table 2). Formation of the pyrido-phenanthrolin-7-one
product was favoured when R was an electron-withdrawing
group (e.g. NO2), whilst electron-donating moieties (e.g. OMe
Fig. 1 Structure of ascididemin.
Fig. 2 Molecular structure of 1a with atomic displacement shown at
50% probability. Only heteroatoms labelled for clarity.
Fig. 3 Molecular structure of 2 with atomic displacement shown at
50% probability. Only heteroatoms labelled for clarity.
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or OH) made the oxazine–phenanthroline the major product.
When R = H, there was no significant selectivity for either
product at this temperature. Also, no significant effect was
observed in the ratio of pyrido : oxazine products in the study
upon reducing the amount of base in the reaction. The first
step in the reaction will be the formation of the Schiff base
which, due to the acidity of the α-H atom, should be in equili-
brium with its 1,5-prototropic tautomer (Scheme 2). We postu-
late this equilibrium as we have previously observed a
H-bonding interaction at the same positions in a Schiff base,
formed from phendione and a hydrazide, between the N–H of
the hydrazide and the carbonyl group on the phenanthroline
core.10a Moreover the carbonyl group of phendione accepts a
H+ fairly readily as in all our cyclisation reactions 1,10-phenan-
throlin-5,6-diol is observed as a side-product.
Metal complexation of pyrido-ligand
The metal coordination ability of the pyrido-phenanthrolin-7-
one-ligand, propyl 7-oxo-4-phenyl-7H-pyrido[4,3,2-de][1,10]phe-
nanthroline-5-carboxylate (1b) was investigated by heating the
ligand with [Re(CO)5Br] in toluene for 3 h under N2. A very
dark-purple precipitate was collected from the solution, using
a centrifuge, and washed with toluene. The product was dried
under vacuum and assigned to be [(1b) (CO)3Re(I)Br] (3).
Crystals were formed by slow evaporation of solvent from a
methanol solution of the complex and the X-ray crystal structure
data were obtained (Fig. 4). Complex 3 is a distorted octahedral
complex and is shown to be the facial isomer and this is consist-
ent with the three intense bands observed in the metal carbonyl
stretching region of the IR spectrum.22 The positions of Br1 and
trans CO group (C33, O34) are disordered and these were mod-
elled at 95 : 5% occupancy with restraints. See ESI Fig. S14.†
There is a halogen–π interaction between Br1 and one ring of
the tetracycle (C6, C8, C16, C17, C18) with a Br–centroid dis-
tance of 3.266(2) Å. There are several other weaker offset π–π
interactions between the tetracycles ranging from 3.4–3.75 Å.
The 1H NMR spectrum recorded of the complex in
DMSO-d6 would suggest that in solution at room temperature
Table 1 Product ratio from the reaction of phendione with
L-phenylalanine methyl ester hydrochloridea over a range of
temperatures
Reaction temperature (°C) Ratio of the pyrido : oxazine productsb
50 1 : 10
60 1 : 5.3
75 1 : 1.8
90 1 : 0.6
a Reactants were heated for 24 h in DMSO in a 1 : 1 mole ratio in the
presence of a slight excess of 1 equivalence of N-methylmorpholine.
b Yield ratio of pyrido : oxazine products is based on the intensity ratio
of the UV/vis bands at 254 nm in the chromatogram of the LC-MS of
the crude reaction mixtures.
Table 2 Product ratio from the reaction of phendione with









NO2 1 : 0.01
4-Nitro-L-phenylalanine methyl ester
hydrochlorideb
NO2 1 : 0.03
4-Trifluoromethyl-L-phenylalanine methyl
ester hydrochloride
CF3 1 : 0.05
L-Phenylalanine methyl ester hydrochloride H 1 : 1.8
4-Methoxy-L-phenylalanine methyl ester
hydrochloride
OMe 1 : 9
L-Tyrosine methyl ester hydrochloride OH 1 : 9
a Reactants were heated at 75 °C for 24 h in DMSO in a 1 : 1 mole ratio
in the presence of a slight excess of 1 equivalence of
N-methylmorpholine. b Same conditions except no N-methylmorpholine
was added to the reaction. c Yield ratio of pyrido : oxazine products is
based on the intensity ratio of the UV/vis bands at 254 nm in the chro-
matogram of the LC-MS of the crude reaction mixtures.
Scheme 2 Formation of the Schiff-base intermediate in the keto–imine
and enol–imine forms.
Fig. 4 Major structural moiety of 3 with 95% occupancy. See ESI† for
further information. Atomic displacement shown at 50% probability.
Heteroatoms labelled only for clarity.
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the complex is fluxional as the peaks arising from the phenyl
moiety are very broad in comparison to those of the unbound
ligand. Preliminary studies indicate that, in contrast to many
tricarbonyl rhenium(I) diimine complexes,23 complex 3 is not
luminescent. This may be explained as for 3 the MLCT absorp-
tion is shifted to long wavelengths (λmax = 504 nm, MeOH) and
previous researchers have proposed that non-luminescent
[(diimine)(CO)3Re(I)L] complexes occur due to low energy
MLCT states resulting in an increase in probability of non-
radiative decay.24,25 The low energy absorptions of the pyrido-
phenanthrol-7-one rhenium complexes may be of interest to
researchers attempting to make rhenium complexes for photo-
dynamic therapy which can be activated by red-NIR light.26,27
Conclusions
In summary we have developed a simple protocol to form a
synthetic analogue of ascididemin from readily available start-
ing materials and in moderate yields. This unusual cyclisation
reaction can be promoted by increasing the reaction tempera-
ture and by introducing an electron-withdrawing group at the
para position of the phenyl ring. The reaction has much scope
and we intend to a produce a family of novel structural ana-
logues and their rhenium(I) tricarbonyl complexes. It would be




All reagents used in chemical syntheses were purchased from
Sigma Aldrich or Fluorochem and were used as supplied. NMR
(Nuclear Magnetic Resonance) spectra were recorded on a
Bruker Avance spectrometer operating at 500 MHz for 1H
nucleus and 125 MHz for the 13C nucleus. The probe tempera-
ture was maintained at 25 °C. All spectra were referenced to
the solvent residual signal. High Resolution Mass
Spectrometry (HRMS) analysis was carried out at Maynooth
University and University of Bath. In Maynooth University, ESI
(electrospray ionization) mass spectra were collected on an
Agilent-L 1200 Series coupled to a 6210 Agilent Time-of-Flight
(TOF) equipped with both a positive and negative electrospray
source. In University of Bath, the HPLC-ESI-TOF analysis was
conducted using an electrospray time-of-flight (MicrOTOF)
mass spectrometer (Bruker Daltonik GmbH, Bremen,
Germany), which was coupled to an Agilent HPLC stack
(Agilent, Santa Clara, CA, United States) consisting of Agilent
G1312A binary pump with G1329A autosampler and G1316A
column oven. Infrared spectra were recorded as KBr discs in
the region 4000–400 cm−1 or on a ATR-ZnSe crystal
4000–650 cm−1 on a PerkinElmer 100 series spectrometer.
UV/vis were recorded in a 1 cm pathlength quartz cuvette on a
PerkinElmer Lambda 35 spectrometer. The HPLC (High
Performance Liquid Chromatography) spectra were extracted
from LC-MS studies that were performed on an Agilent
Technologies 1200 Series instrument consisting of a G1322A
Quaternary pump and a G1314B UV detector (254 nm) coupled
to an Advion Expression L Compact Mass spectrometer (ESI)
operating in positive mode. Separations were performed on a
Waters Xbridge OST 2.5 µm, 4.6 × 50 mm column (C18) operat-
ing at a flow rate of 0.2 mL min−1. Separations were performed
using a mobile phase of 0.1% formic acid in water (Solvent A)
and 0.1% formic acid in acetonitrile (Solvent B) and a linear
gradient of 0–100% B over 30 min.
Synthetic procedures
1,10-Phenanthroline-5,6-dione and the esters of the amino
acid hydrochloride were synthesised using literature
procedures.28,29 All amino acid ester hydrochlorides used are
previously reported compounds. The generalised procedure to
synthesise the amino acid esters is as follows: Acetyl chloride
(4.352 mL, 60.99 mmol) was added to a cold solution of the
required alcohol (1.40 mol). To this, the amino acid
(11.04 mmol) was added and the resulting clear colourless
solution was refluxed for 3 h. The resulting solution was fil-
tered and then reduced to 10 mL on a rotary evaporator. The
product was precipitated via addition of 400 mL diethyl ether.
The resulting suspension was filtered and washed with 3 ×
50 mL portions of diethyl ether and dried under vacuum to
yield white solids.
Synthesis of phenanthroline ligands
The appropriate amino acid ester hydrochloride salt
(1.00 mmol) was dissolved in DMSO and to this solution,
N-methylmorpholine (slight excess of 1 eq.) was added. The
solution was heated to 75 °C while being constantly stirred
and phendione was then added to give a bright yellow solu-
tion. After constant stirring at 75 °C for 24 h, a clear bright
orange solution was observed and mixed with 125 mL of DCM.
The organic layer was washed with 5 × 125 mL portions of H2O
and then dried over MgSO4. The resulting DCM solution was
condensed to dryness on a rotary evaporator to give the crude
product.
Methyl 7-oxo-4-phenyl-7H-pyrido[4,3,2-de][1,10]phenanthro-
line-5-carboxylate (1a). L-Phenylalanine methyl ester hydro-
chloride (0.215 g, 1.00 mmol), N-methylmorpholine (0.121 mL,
1.10 mmol), phendione (0.210 g, 1.00 mmol), DMSO (25 mL),
24 h. A 1H NMR spectrum recorded of the mixture showed
signals for the desired product and for the corresponding phe-
nanthroline–oxazine compound. The product mixture was dis-
solved in MeOH (3 mL) to which EtOAC (5 mL) was added and
was left in the freezer (−20 °C) for 72 h. 1a formed as bright
yellow crystals (0.026 g, 7%); m.p.: decomp. @ 230 °C; HRMS
(ESI+): calculated m/z for C22H13N3O3: (M + Na)
+ 390.0849;
found: (M + Na)+ 390.0863; difference (ppm): 3.59; LC-MS rt
(23.08 min, 97% purity); IR (KBr, cm−1) 3434, 1729, 1678,
1578, 1439, 1376, 1280, 1258, 1234, 1202, 1167, 1002, 702, 676,
607. 1H NMR (DMSO-d6, 500 MHz): δ 9.12–9.09 (m, 1H,
PhenH), 9.02 (d, J = 5.9 Hz, 1H, PhenH), 8.62 (dd, J = 7.9,
1.6 Hz, 1H, PhenH), 7.82 (dd, J = 7.9, 4.6 Hz, 1H, PhenH),
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7.69–7.60 (m, 4H, PhenH + 3ArH), 7.51–7.46 (m, 2H, ArH), 3.70
(s, 3H, –OCH3).
13C NMR (DMSO-d6, 125 MHz): δ 181.0 (CvO),
166.7 (CvO), 155.3 (PhenC), 151.7 (PhenC), 150.7 (PhenC),
149.0 (PhenC), 147.5 (αC), 146.4 (PhenCvN), 138.5 (PhenC),
135.9 (PhenC), 135.4 (ArC), 133.5 (βC), 130.2 (ArC), 129.7 (ArC),
129.4 (PhenC), 129.2 (ArC), 126.6 (PhenC), 120.8 (PhenC),
119.8 (PhenC), 53.1 (–OCH3).
Propyl 7-oxo-4-phenyl-7H-pyrido[4,3,2-de][1,10]phenanthro-
line-5-carboxylate (1b). L-Phenylalanine propyl ester hydro-
chloride salt (0.244 g, 1.00 mmol), N-methylmorpholine
(0.121 mL, 1.10 mmol), phendione (0.210 g, 1.00 mmol),
DMSO (25 mL) 24 h, a clear bright orange solution was
observed and mixed with 125 mL of DCM. A 1H NMR spectrum
recorded of the mixture showed signals for the desired product
and for the corresponding phenanthroline–oxazine com-
pound. The crude product was dissolved in warm diethyl
ether. The solution was allowed to cool and 1b precipitated as
a yellow solid and was collected by filtration. (0.073 g, 18%);
m.p.: decomp. @ 230 °C; HRMS (ESI+): calculated m/z for
C24H17N3O3: (M + Na)
+ 418.1162; found: (M + Na)+ 418.1164;
difference (ppm) 0.5; LC-MS rt (26.51 min, 91% purity); IR
(KBr, cm−1) 3434, 1728, 1676, 1579, 1441, 1378, 1281, 1259,
1232, 1200, 1169, 1001, 705, 679, 606. 1H NMR (DMSO-d6,
500 MHz): δ 9.15–9.14 (m, 1H, PhenH), 9.07 (d, J = 5.9 Hz, 1H,
PhenH), 8.66 (dd, J = 7.9, 1.6 Hz, 1H, PhenH), 7.85 (dd, J = 7.9,
4.6 Hz, 1H, PhenH), 7.71–7.62 (m, 4H, PhenH + 3ArH),
7.53–7.47 (m, 2H, ArH), 4.06 (t, J = 6.5 Hz, 2H, –OCH2), 1.37
(dt, J = 7.3, 6.5 Hz, 2H, CH2), 0.70 (t, J = 7.3 Hz, 3H, CH3).
13C
NMR (DMSO-d6, 125 MHz): δ 181.1 (CvO), 166.5 (CvO), 155.3
(PhenC), 151.8 (PhenC), 150.8 (PhenC), 149.1 (PhenC), 148.0
(αC), 146.6 (PhenCvN), 138.5 (PhenC), 136.0 (PhenC), 135.0
(ArC), 133.6 (βC), 130.3 (ArC), 129.8 (ArC), 129.5 (PhenC), 129.3
(ArC), 126.6 (PhenC), 120.9 (PhenC), 119.8 (PhenC), 67.58
(–OCH2), 21.6 (CH2), 10.6 (CH3).
Ethyl 4-(4-nitrophenyl)-7-oxo-7H-pyrido[4,3,2-de][1,10]phe-
nanthroline-5-carboxylate (1c). 4-Nitro-L-phenylalanine ethyl
ester hydrochloride salt (0.262 g, 1.00 mmol),
N-methylmorpholine (0.121 mL, 1.10 mmol), phendione
(0.210 g, 1.00 mmol), DMSO (25 mL), 24 h. The crude product
was dissolved in 10 mL EtOH and allowed to stand overnight.
The resulting suspension was filtered, washed with 3 × 10 mL
portions of cold EtOH and dried under vacuum to yield a
bright red solid (0.132 g, 30%); m.p. >250 °C; HRMS (ESI+):
calculated m/z for: (C23H14N4O5 + Na)
+ [M + Na]+ 449.0856,
found: 449.0878, difference (ppm) 4.89; LC-MS: rt (24.71 min,
90% purity); IR (KBr, cm−1) 3429, 2927, 1723, 1683, 1598,
1581, 1505, 1345, 1291, 1204, 1104, 859, 709. 1H NMR (DMSO-
d6, 500 MHz): δ 9.15 (dd, J = 4.6, 1.8 Hz, 1H, PhenH), 9.07 (d,
J = 5.9 Hz, 1H, PhenH), 8.67 (dd, J = 7.9, 1.8 Hz, 1H, PhenH),
8.53–8.45 (m, 2H ArH), 7.86 (dd, J = 7.9, 4.6 Hz, 1H, PhenH),
7.83–7.78 (m, 2H, ArH), 7.61 (d, J = 5.9 Hz, 1H PhenH), 4.19 (q,
J = 7.1 Hz, 2H, –OCH2), 1.04 (t, J = 7.1 Hz, 3H, CH3).
13C NMR
(DMSO-d6, 125 MHz): δ 181.1 (CvO), 165.6 (CvO), 155.4
(PhenC), 151.7 (PhenC), 150.8 (PhenC), 149.3 (PhenC), 148.4
(ArC), 147.3 (αC), 146.8 (PhenCvN), 141.0 (ArC), 138.5
(PhenC), 136.1 (PhenC), 134.10 (βC), 131.8 (ArC), 129.5
(PhenC), 126.7 (PhenC), 124.2 (ArC), 120.8 (PhenC), 119.7
(PhenC), 62.3 (–OCH2), 14.0 (CH3).
Propyl 2 phenyl-2H-[1,4]oxazino[2,3-f ][1,10]phenanthroline-
3-carboxylate (2). L-Phenylalanine propyl ester hydrochloride
(0.243 g, 1.00 mmol), N-methylmorpholine (0.121 mL,
1.10 mmol), phendione (0.210 g, 1.00 mmol), DMSO (25 mL),
24 h. A 1H NMR recorded of the reaction mixture showed
signals which are indicative of the formation of both the phe-
nanthroline–oxazine and the pyrido-phenanthrolin-7-one pro-
ducts. The crude product was dissolved in warm diethyl ether.
The solution was allowed to cool and 2 slowly crystallised from
the mixture as orange crystals and was collected by filtration.
(0.011 g, 3%) HRMS (ESI+): calculated m/z for: (C24H19N3O3 +
H)+ [M + H]+ 398.1499, found: 398.1500, difference (ppm) 0.30.
IR (KBr, cm−1) 3429, 2927, 1723, 1683, 1598, 1581, 1505, 1345,
1291, 1204, 1104, 859, 709. 1H NMR (DMSO-d6, 500 MHz) δ
9.12 (dd, J = 4.3, 1.8 Hz, 1H, PhenH), 9.02 (dd, J = 4.3, 1.7 Hz,
1H, PhenH), 8.84 (dd, J = 8.3, 1.7 Hz, 1H, PhenH), 8.62 (dd, J =
8.3, 1.8 Hz, 1H, PhenH), 7.83 (dd, J = 8.3, 4.3 Hz, 1H, PhenH),
7.79 (dd, J = 8.3, 4.3 Hz, 1H, PhenH), 7.43–7.37 (m, 2H, ArH),
7.34–7.26 (m, 3H, ArH), 6.70 (s, 1H, βH), 4.27 (m, 2H, OCH2),
1.75–1.60 (m, 2H, CH2), 0.91 (t, J = 7.4 Hz, 3H, CH3).
13C NMR
(DMSO-d6, 125 MHz): δ 162.5 (CvO), 152.1 (PhenCH), 150.4
(αC), 149.2 (PhenCH), 146.9 (PhenC), 142.8 (PhenC), 138.8
(PhenC), 135.5 (ArC), 131.4 (PhenCH), 130.3 (PhenCH), 130.1
(ArC), 129.6 (ArC), 127.5 (Ar C), 126.4 (PhenC), 124.6
(PhenCH), 124.3(PhenCH), 122.2(PhenC), 121.5 (PhenC), 72.6
(βC), 67.8 (–OCH2), 21.9 (CH2), 10.6 (CH3).
fac-Bromotricarbonyl (propyl 7-oxo-4-phenyl-7H-pyrido
[4,3,2-de][1,10]phenanthroline-5-carboxylate) rhenium(I) (3).
Re(CO)5Br (20 mg, 0.05 mmol) and 1b (20 mg, 0.05 mmol)
were added to a 10 mL pressure tube. Dried degassed toluene
(10 mL) was added to the tube and N2 gas was bubbled slowly
through the solution for 30 min. A stirring bead was added to
the tube and the tube was sealed and then heated for 3 h at
110 °C with stirring. The solution went very dark purple and
the dark purple product was collected using a centrifuge and
washed with toluene and the centrifuge collection was
repeated. The residual toluene was removed under vacuum
(26 mg, 70%). HRMS (ESI+): calculated m/z for:
(C27H17BrN3O6Re + Na)
+ [M + Na]+ 767.9750, found:767.9724,
difference (ppm) 3.4. IR (ATR, cm−1) 2021 (Re–CO), 1922 (Re–
CO), 1900 (Re–CO), 1736 (propyl ester CO), 1690 (phen–CO).
1H NMR (DMSO-d6, 500 MHz): δ 9.41 (d, J = 5.5 Hz, 1H,
PhenH), 9.15 (d, J = 6.5 Hz, 1H, PhenH), 8.97 (d, J = 7.9, 1H,
PhenH), 8.12 (dd, J = 7.9, J = 5.5 1H, PhenH), 7.96 (d, J = 6.5
Hz, 1H, PhenH), 7.67(s(br), 3H, ArH), 7.56 (s(br), 2H, ArH),
4.09 (t, J = 6.4 Hz, 2H, –OCH2), 1.49–1.28 (m, 2H, CH2), 0.70 (t,
J = 7.4 Hz, 3H, CH3).
13C NMR (DMSO-d6, 125 MHz): δ 197.1
(Re–CO), 196.9 (Re–CO), 187.9 (Re–CO), 178.0 (phen–CO),
166.0 (ester–CO), 157.3 (PhenCH), 154.3 (PhenC),
153.8 (PhenC), 150.4 (PhenCH), 149.6(αC), 146.2 (PhenCvN),
138.2(PhenCH), 138.1 (PhenC), 134.7 (βC), 132.6 (ArC),
132.1 (PhenC), 130.4 (PhenCH), 130.2 (ArC × 3), 129.5(ArC × 2),
124.4 (PhenCH), 121.5 (PhenC), 67.9 (OCH2), 21.5 (CH2),
10.5 (CH3).
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X-Ray crystallography: Data for samples 1a, 2 and 3 were col-
lected on a Bruker D8 Quest ECO (1a) using Mo Kα (λ =
0.71073 Å) and a APEX DUO Kappa system (3 and 2) using Cu
Kα (λ = 1.54184 Å) radiation. Samples were mounted on a
MiTeGen microloop and data collected at 100(2) K using an
Oxford Instruments Cryostream and Cobra low temperature
device. Bruker APEX (Bruker 2016) software was used to collect
and reduce data and determine the space group. Structures
were solved with the XT30 structure solution program using
Intrinsic Phasing and refined with the XL31 refinement
package using Least Squares minimisation with Olex2.32
Absorption corrections were applied using SADABS (Bruker
2016/2). Crystal data, details of data collection and refinement
are given in Table S1.† In structure 3, Br1 and trans CO groups
(C33, O34) were disordered and modelled in two positions
with 95 : 5% occupancy with restraints (DFIX, SADI, SIMU). In
2, the C9 chiral centre is represented as S. As this is a centro-
symmetric space group (P1̄), the structure is a racemate.
CCDC 1941514–1941516† contains the supplementary crys-
tallographic data for this paper.
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